Therefore, we showed that, the grouping of MM patients according to 1q&13 classification might recapitulate the results of transcriptome-based patients’ stratification: in fact, 1q&13+ subgroup of patients corresponds to those classified as proliferation-associated genes (PR), translocation cluster (MF) and bone disease (LB) by the most recent TC classification, whereas 1q&13- subgroup, overexpressing CCND1, corresponds to hyperdiploid (HY), CD-1 and CD-2 subgroups of patients, defined low risk and at good prognosis22. Here, CD2 is linked to Miyoshi myopathy.